MedTrace Logo

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

NCT02521714 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-11-08

No results posted yet for this study

Summary

This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation. The study will also examine the effect of a high fat meal on the levels of drug in blood.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Lenalidomide

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Francisco Ramirez-Valle, MD, PhD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-14
Primary Completion
2015-09-23
Completion
2015-09-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521714 on ClinicalTrials.gov